Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: the Survey of PatIents with treatment ResIstant hyperTension study.

OBJECTIVE We evaluated the characteristics of patients with treatment-resistant hypertension (TRH) and the prevalence of TRH in a large multicountry sample of specialist tertiary centres. METHODS The Survey of PatIents with treatment ResIstant hyperTension (SPIRIT) study was a retrospective review of medical records of patients seen at tertiary centres located in Western Europe, Eastern Europe, North America, South America, Australia and Asia. Data on demographics, medical history and medication use were extracted from medical records. Prevalence and incidence of TRH were based upon estimated catchment populations. RESULTS On thousand, five hundred and fifty-five patients from 76 centres were included, mostly from centres that specialize in hypertension (55%), cardiology (11%) or nephrology (19%). Mean age was 64, 60% were men, 62% were Caucasian, 36% had chronic kidney disease, 41% had diabetes, 12% were smokers and 31% had a previous cardiovascular event. Daytime and night-time ambulatory blood pressure (BP) was the most frequently used measurement for diagnosis (82%). Ninety-five percent of patients were prescribed diuretics, 93% an inhibitor of the renin-angiotensin system, 86% a calcium channel blocker, 74% a beta-blocker and 36% an aldosterone antagonist. The overall estimated mean incidence of TRH was 5.8 per 100 000 per year (ranging between 2.3 and 14.0 across regions) and the corresponding estimated mean prevalence of TRH was 23.9 per 100 000 (ranging between 7.6 and 90.5 across regions). CONCLUSION Observed variation likely reflects real differences in patient characteristics and physician management practices across regions and specialities but may also reflect differences in patient selection and errors in estimation of catchment population across participating centres.

[1]  Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[2]  David A Calhoun,et al.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. , 2018, Hypertension.

[3]  Thomas Kahan,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[4]  J. R. Nansseu,et al.  Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients , 2018, Heart.

[5]  D. Prabhakaran,et al.  May Measurement Month 2017: an analysis of blood pressure screening results worldwide. , 2018, The Lancet. Global health.

[6]  J. Williamson,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Hypertension.

[7]  W. Spiering,et al.  Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care , 2017, BMJ Open.

[8]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[9]  M. Ng,et al.  Prevalence, clinical characteristics and echocardiography parameters of non-resistant, resistant and refractory hypertension in Chinese , 2017, Postgraduate medicine.

[10]  Steven M. Smith,et al.  Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014 , 2016, Hypertension.

[11]  K. Reynolds,et al.  Global Disparities of Hypertension Prevalence and ControlClinical Perspective , 2016 .

[12]  A. Høieggen,et al.  Tertiary work-up of apparent treatment-resistant hypertension , 2016, Blood pressure.

[13]  G. Bakris,et al.  The double challenge of resistant hypertension and chronic kidney disease , 2015, The Lancet.

[14]  S. Frey,et al.  Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. , 2015, American journal of hypertension.

[15]  A. Oliveras,et al.  Resistant hypertension: do all definitions describe the same patients? , 2015, Journal of Human Hypertension.

[16]  B. Davis,et al.  Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal DiseaseNovelty and Significance , 2014 .

[17]  B. Davis,et al.  Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease: Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2014, Hypertension.

[18]  Alan S. Brown,et al.  Proceedings from Duke resistant hypertension think tank. , 2014, American heart journal.

[19]  J. Bisognano,et al.  The prevalence, incidence, prognosis, and associated conditions of resistant hypertension. , 2014, Seminars in nephrology.

[20]  S. Oparil,et al.  Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort , 2014, Hypertension.

[21]  D. Calhoun,et al.  Apparent and true resistant hypertension: definition, prevalence and outcomes , 2014, Journal of Human Hypertension.

[22]  Philippe Van De Borne,et al.  Guidelines for the management of arterial hypertension , 2014 .

[23]  V. Pavlik,et al.  Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence. , 2013, Journal of the American Society of Hypertension : JASH.

[24]  H. Krum,et al.  RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials , 2013, Cardiovascular Drugs and Therapy.

[25]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[26]  J. Marrs,et al.  Description of Antihypertensive Use in Patients With Resistant Hypertension Prescribed Four or More Agents , 2011, Hypertension.

[27]  N. Poulter,et al.  Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk , 2011, Journal of hypertension.

[28]  J. Banegas,et al.  Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring , 2011, Hypertension.

[29]  C. McAdam-Marx,et al.  Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. , 2009, Clinical therapeutics.

[30]  Daniel W. Jones,et al.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.